-$1.22 Earnings Per Share Expected for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) This Quarter


Share on StockTwits

Analysts expect that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will post earnings per share of ($1.22) for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($0.93) and the lowest estimate coming in at ($1.80). Ultragenyx Pharmaceutical reported earnings of ($2.04) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 40.2%. The firm is scheduled to issue its next earnings results on Wednesday, May 5th.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($4.81) per share for the current year, with EPS estimates ranging from ($5.69) to ($3.88). For the next fiscal year, analysts forecast that the firm will report earnings of ($4.21) per share, with EPS estimates ranging from ($6.04) to ($1.22). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Ultragenyx Pharmaceutical.

A number of equities research analysts have weighed in on the company. TheStreet upgraded Ultragenyx Pharmaceutical from a “d” rating to a “c-” rating in a research report on Tuesday, February 16th. Zacks Investment Research cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating and set a $152.00 target price for the company. in a research note on Wednesday, February 17th. Credit Suisse Group lifted their target price on Ultragenyx Pharmaceutical from $64.00 to $99.00 and gave the stock a “neutral” rating in a report on Monday, January 25th. Piper Sandler upped their price target on shares of Ultragenyx Pharmaceutical from $165.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, February 12th. Finally, Stifel Nicolaus assumed coverage on shares of Ultragenyx Pharmaceutical in a report on Monday, March 1st. They issued a “buy” rating and a $179.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $132.50.

Shares of NASDAQ:RARE opened at $105.27 on Thursday. The company has a 50 day moving average of $125.80 and a 200-day moving average of $125.00. The firm has a market cap of $7.05 billion, a P/E ratio of -23.98 and a beta of 2.19. Ultragenyx Pharmaceutical has a twelve month low of $50.22 and a twelve month high of $179.65.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 30,000 shares of the business’s stock in a transaction dated Monday, March 1st. The stock was sold at an average price of $141.80, for a total value of $4,254,000.00. Following the completion of the sale, the chief executive officer now owns 596,941 shares of the company’s stock, valued at $84,646,233.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director William Aliski sold 7,500 shares of the company’s stock in a transaction dated Friday, February 19th. The stock was sold at an average price of $149.01, for a total value of $1,117,575.00. Following the sale, the director now owns 73,204 shares of the company’s stock, valued at approximately $10,908,128.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,245 shares of company stock worth $7,637,704. Insiders own 8.20% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Norges Bank bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth $77,444,000. UBS Asset Management Americas Inc. grew its position in shares of Ultragenyx Pharmaceutical by 4.7% in the fourth quarter. UBS Asset Management Americas Inc. now owns 68,401 shares of the biopharmaceutical company’s stock valued at $9,469,000 after purchasing an additional 3,066 shares during the last quarter. Hsbc Holdings PLC increased its stake in shares of Ultragenyx Pharmaceutical by 89.3% in the fourth quarter. Hsbc Holdings PLC now owns 9,962 shares of the biopharmaceutical company’s stock worth $1,397,000 after purchasing an additional 4,699 shares during the period. Virtu Financial LLC bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter worth about $1,966,000. Finally, WCM Investment Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 5.8% during the 4th quarter. WCM Investment Management LLC now owns 71,729 shares of the biopharmaceutical company’s stock worth $9,929,000 after purchasing an additional 3,917 shares during the last quarter.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders.

See Also: Rule of 72

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.